Compare GNTX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNTX | LQDA |
|---|---|---|
| Founded | 1974 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 1995 | 2020 |
| Metric | GNTX | LQDA |
|---|---|---|
| Price | $22.86 | $68.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $26.60 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | 1.00 | ★ 1.26 |
| Revenue | ★ $2,534,268,965.00 | $158,320,000.00 |
| Revenue This Year | $6.89 | $278.87 |
| Revenue Next Year | $4.58 | $57.13 |
| P/E Ratio | ★ $23.06 | $55.51 |
| Revenue Growth | 9.55 | ★ 1031.18 |
| 52 Week Low | $20.48 | $21.15 |
| 52 Week High | $29.38 | $93.61 |
| Indicator | GNTX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 36.87 |
| Support Level | $22.33 | $31.99 |
| Resistance Level | $24.15 | $92.35 |
| Average True Range (ATR) | 0.48 | 4.48 |
| MACD | -0.05 | -1.26 |
| Stochastic Oscillator | 2.26 | 4.15 |
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.